New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs

J&J’s Janssen Biotech subsidiary won FDA approval for the IL-12/IL-23 inhibitor Stelara to treat Crohn’s disease, giving it a second-line position alongside anti-TNF therapies for patients in need of new options.

ApproveOnKeyboard_1200x675

US FDA approval for Janssen Biotech Inc.’s Stelara (ustekinumab) for the treatment of Crohn’s disease puts the interleukin 12 (IL-12) and IL-23 inhibitor on equal second-line footing with anti-tumor necrosis factor (TNF) therapies – the indication’s leading class of biologics.

Janssen, a Johnson & Johnson subsidiary, noted that Stelara is the first drug targeting IL-12 and IL-23 that’s approved...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip